BioWorld MedTech

Sep. 3, 2010

Spine market facing growth challenges, analyst says

Right now it's better to be a smaller, well-capitalized spine company with a broad product line than a larger spine company, according to one analyst who covers the space. (Medical Device Daily) Read More

Study shows Cepheid's test is an 'Xpert' in diagnosing TB

SYNTAX creates common ground for coronary risk assessment

Washington roundup: Alphatec warned after taking back some manufacturing work

Holiday notice

Med-Tech Notes

Deals roundup: Erba buys most of Ivax shares for $15M

MDD's food for med-tech thought

Agreements/contracts: LifeCell to distribute Novadaq's SPY imaging

Courts report: Allergan to pay $600M to settle Botox-related charges

Financings roundup: AHP discloses results of self-tender offer

Restructuring roundup: Angeion restructures board and names two new officers

People in the News

Product Briefs

MDD's Diagnostic Extra

Today's news in brief

BioWorld

BioWorld briefs for May 21, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...